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BRIEF DEFINITIVE REPORT
A stromal cell niche sustains ILC2-mediated type-2
conditioning in adipose tissue
Batika M.J. Rana1, Eric Jou1, Jillian L. Barlow1, Noe Rodriguez-Rodriguez1, Jennifer A. Walker1, Claire Knox1, Helen E. Jolin1, Clare S. Hardman1,
Meera Sivasubramaniam1, Aydan Szeto1, E. Suzanne Cohen2, Ian C. Scott2, Matthew A. Sleeman2, Chiamaka I. Chidomere3, Sara Cruz Migoni3,
Jorge Caamano3, Helle F. Jorgensen4, Stefania Carobbio5,6, Antonio Vidal-Puig5,6, and Andrew N.J. McKenzie1
Group-2 innate lymphoid cells (ILC2), type-2 cytokines, and eosinophils have all been implicated in sustaining adipose tissue
homeostasis. However, the interplay between the stroma and adipose-resident immune cells is less well understood. We
identify that white adipose tissue–resident multipotent stromal cells (WAT-MSCs) can act as a reservoir for IL-33, especially
after cell stress, but also provide additional signals for sustaining ILC2. Indeed, we demonstrate that WAT-MSCs also support
ICAM-1–mediated proliferation and activation of LFA-1–expressing ILC2s. Consequently, ILC2-derived IL-4 and IL-13 feed back to
induce eotaxin secretion from WAT-MSCs, supporting eosinophil recruitment. Thus, MSCs provide a niche for multifaceted
dialogue with ILC2 to sustain a type-2 immune environment in WAT.
Introduction
Group-2 innate lymphoid cells (ILC2s) respond rapidly at
mucosal surfaces to combat infection but also contribute to
the maintenance of tissue repair and homeostasis (Vivier
et al., 2018). Signals within the tissue microenvironment
help dictate the phenotype of resident ILC2s, equipping them
with attributes commensurate with the physiological re-
quirements of their location (Ricardo-Gonzalez et al., 2018).
White adipose tissue (WAT)–resident ILC2s contribute to the
maintenance of metabolic homeostasis (Molofsky et al., 2013;
Brestoff et al., 2015; Lee et al., 2015), and receive signals from
adipocytes and stromal vascular fraction (SVF)–derived cells
(Dykstra et al., 2017; Dahlgren et al., 2019; Mahlakõiv et al.,
2019). Notably, lean WAT is distinguished by a type-2 immune
environment populated by alternatively activated M2 mac-
rophages, eosinophils, ILC2, regulatory T cells, and cytokines
including IL-4, IL-5, IL-13, and IL-33 (Cipolletta et al., 2012;
Bapat et al., 2015; Molofsky et al., 2015; Schwartz et al., 2016;
Lee et al., 2018). By contrast, low-grade type-1 inflammation,
characterized by classically activated M1 macrophages, Th1
cells, and cytokines including IL-1β, IL-18, TNFα, and IL-8, is
associated with increased obesity (Weisberg et al., 2003;
Odegaard and Chawla, 2015; Schwartz et al., 2016; Kumari
et al., 2018).
In mice, administration of IL-33 induced ILC2 activation and
promoted beiging of adipocytes, a process associated with in-
creased metabolic consumption (Brestoff et al., 2015; Lee et al.,
2015). A number of mechanisms appear to underlie these
changes. ILC2s were shown to produce the endogenous opioid
peptide Met-enkephalin that may contribute to regulating obe-
sity (Brestoff et al., 2015). Others reported that ILC2, along with
eosinophils (Wu et al., 2011), produce IL-4 and/or IL-13, which
directly promote beiging of adipocyte progenitors (Lee et al.,
2015). IL-5–producing ILC2s were also required to sustain IL-
4–secreting eosinophils in visceral adipose tissue (Molofsky
et al., 2013), and mice lacking eosinophils gained more weight
(Wu et al., 2011). These studies support key roles for IL-33, ILC2,
and eosinophils in regulating a lean phenotype.
Here, we aim to clarify the stromally elicited signals sus-
taining a type-2 immune microenvironment in healthy adipose
tissue homeostasis by interrogating the mechanisms by which
multipotent stromal cells (MSCs) and ILC2s communicate within
this niche.
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Results and discussion
Consistent with other data (Molofsky et al., 2013), WAT was
enriched with IL-33–receptor ST2hi ILC2s (Fig. S1, A–E), and
ILC2-deficient (Rorafl/flIl7racre) mice displayed markedly reduced
WAT IL-13 and IL-5 expression and decreased eosinophil fre-
quency (Fig. S1, F–L). Given the prominent role of IL-33 in
supporting ILC2 proliferation, we used Il33-citrine reporter mice
(Hardman et al., 2013) to identify stromal cells as the major
source of Il33-citrine expression in WAT, constituting ∼87% of
CD45–PDGFRα+ mesenteric WAT stromal cells, ∼62% in the in-
guinal adipose tissue, and∼41% in the perigonadal fat pad (Fig. 1,
A–C; and Fig. S1 M). These Il33-citrine+ cells were located around
the endothelial layer in the mesentery (Fig. 1 D), a position akin
to that reported for mesenchymal stem cells or pericytes
(Corselli et al., 2010; Dahlgren et al., 2019); and surrounding fat-
associated lymphoid clusters (Fig. S1 N). Western blot analysis of
purified WAT stromal cells confirmed their expression of full-
length IL-33 (Fig. 1 E).
Flow cytometry, gene expression profiles, and princi-
pal component analysis established that adipose-resident
CD45–PDGFRα+Il33-citrine+or– stromal cells (CD45–FAP+CD90+
podoplanin+EpCAM–CD24–Tie2-GFP–CD29+CD73+CD34+Sca1[Ly6a]+
CD63+vimentin[Vim]+) were distinct from other known IL-
33–expressing populations: epithelial cells (CD45–CD31–EpCAM+
E-cadherin[Cdh1]+ surfactant protein B[Sftbp]+); endothelial cells
(CD45–CD31+EpCAM–CD36+podocalyxin[Podxl]+lymphatic vessel
endothelial hyaluronan receptor 1[Lyve1]+); pericytes (Dlk1+
Cspg4+CD146[Mcam]+Pparg+angiopoietin-1 and -2[Angpt1 and 2]+);
and PDGFRα–CD31+Tie2-GFP+ endothelial progenitors (Fig. 1, F–H;
and Fig. S2, A–C). Gene expression for known ILC2-activating
factors including Il7, Il2, Il25, Tslp, and Kitl (SCF), as well as Il1rl1
(IL-33 receptor, ST2), was negligible in PDGFRα+Il33-citrine+or–
WAT stromal cells (Fig. 1 H and data not shown). These data
suggested that IL-33 was the predominant ILC2-inducing cytokine
produced by WAT stromal cells, and unlike a previous report, we
were unable to detect TSLP, perhaps due to the differences be-
tween WAT and lung stromal cells (Dahlgren et al., 2019). Al-
though we identified Il33-citrine+or– WAT stromal cells these were
found to be highly similar with respect to phenotype and gene
expression (Fig. 1 I).
WAT stromal cells have a gene expression profile charac-
teristic of MSCs, which have the ability to differentiate into
multiple cell lineages (Cawthorn et al., 2012; Farahani and
Xaymardan, 2015). Indeed, PDGFRα+Il33-citrine+or– stromal
cells cultured in vitro with defined adipogenic factors readily
differentiated into LipidTOX Red–staining lipid-storing mature
adipocytes (Fig. 1 J and data not shown), similar to a positive
control constituting the SVF from perigonadal adipose tissue
(Fig. 1 J). Furthermore, PDGFRα+Il33-citrine+ WAT stromal cells
also possessed myogenic potential when cultured in vitro with
PDGF and TGFβ, giving rise to proliferating 5-ethynyl-29-deox-
yuridine (EdU)+ α-smooth muscle actin–positive cells in culture,
resembling a positive control from aorta adventitia (Fig. 1 K).
Consequently, we subsequently refer to these cells as WAT-
MSCs. Recently, IL-33 expression has been reported in stromal
cells in multiple tissues (Heredia et al., 2013; Kuswanto et al.,
2016; Dalmas et al., 2017; Dahlgren et al., 2019; Mahlakõiv et al.,
2019; Spallanzani et al., 2019), suggesting that similar cells may
represent an important source of IL-33 for maintaining ho-
meostasis and repair throughout the body.
Given the conserved phenotype and gene expression of Il33-
citrine+and– WAT-MSCs, we subsequently used totalWAT-MSCs,
independent of their Il33-citrine expression, to assess their po-
tential to regulate ILC2 biology. We found that co-culture of
WAT-MSCs with naive WAT-ILC2s (Fig. S3, A and B), induced
ILC2 proliferation (Fig. 2, A and B) and IL-5 expression,
as compared with cultures lacking WAT-MSCs (Fig. 2, C
and D). Unexpectedly, these effects were predominantly IL-
33–independent, as ILC2 proliferation was largely unchanged
when IL-33–deficient WAT-MSCs were used in this assay (Fig. 2,
A–D). We also excluded a potential role for contaminating MSCs
by confirming the result using both IL-33–deficient ILC2 and
MSCs (Fig. S3 C). Nevertheless, we did observe that MSC-
derived IL-33 was required to elicit up-regulation of the ILC2
activation marker KLRG1 in two of three experiments, but not
GATA3 (Fig. 2, E and F). It has been proposed that cell stress and
damage are required to trigger IL-33 release in vivo (Moussion
et al., 2008; Scott et al., 2018). Consequently, to replicate in situ
cell stress/damage, the SVF from WT or IL-33–deficient mice
was freeze-thawed to induce IL-33 release (Fig. 2 G), and su-
pernatants were added to ILC2 cultures. Supernatants from
IL-33–deficient SVF were less efficient at stimulating ILC2 pro-
liferation (Fig. 2 H), KLRG1 up-regulation (Fig. 2 I), and GATA3
expression (Fig. 2 J) than WT samples. Taken together, these
results suggest that WAT-MSCs express IL-33 in healthy WAT
and are capable of releasing IL-33 release upon cellular stress or
damage. Indeed, a recent report has demonstrated that absence
of IL-33 from PDGFRα+ stromal cells reduced the type-2 response
in the lung following helminth infection (Dahlgren et al., 2019).
However, even in the absence of IL-33, we observed that
MSCs provided additional signals to support a type-2 immune
microenvironment, results supported by the fact that depletion
of IL-33+ MSCs, even with supplementation of exogenous IL-
33, causes a reduction in the proportion of ILC2 in the lung
(Dahlgren et al., 2019). To identify the IL-33–independent
pathway through which WAT-MSCs regulate ILC2 prolifera-
tion, we determined if the factor was secreted or cell-bound.
Time-course analysis confirmed the enhanced proliferation of
ILC2 co-cultured in the presence of MSCs over 5 d, accompanied
by the up-regulation of the activation marker KLRG1 (Fig. 3 A).
Co-culture of purified WAT-MSCs with ILC2 resulted in in-
creased total cell counts (Fig. 3 B), which were ablated when the
ILC2 and MSCs were separated using transwells (Fig. 3 B),
though in part, this was due to the reduced survival of ILC2 on
the transwell filter (Fig. S3 D). However, we also observed en-
hanced ILC2 proliferation, as determined by cell trace violet
(CTV) staining (Fig. 3 C), which was reversed in the transwell
culture, and was independent of the substrate on which they
were cultured (Fig. 3 C). Similarly, MSC-induced, ILC2-derived
IL-5 production was also reduced when the cells were separated
in transwell assays (Fig. 3 D).
To isolate the cell surface–associated proliferative/main-
tenance signal, we interrogated WAT-MSC and WAT-ILC2
gene expression data for potential ligand/counter-ligand pairs.
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Figure 1. Adipose resident IL-33+ cells are MSCs. (A) Gating strategy. CD45–EpCAM+ epithelial cells (Epi), CD45–CD31+ endothelial cells (End), and
CD45–EpCAM–CD31–PDGFRα+CD34+ stromal cells. SSC-A, side scatter area; FSC-A, forward scatter area. (B) Proportion of Il33-citrine–positive cells in tissues
from Il33cit/+ mice (n = 4, representative of two similar independent experiments). (C) Proportion of Il33-citrine+or–CD45–EpCAM–PDGFRα+ stromal cells among
live cells in indicated tissues (n = 4). (D) Histology of WT or Il33cit/+ mesentery: tomato lectin stain of capillary lumen. Scale bars, 50 µm. (E) Western blot
analysis of IL-33 protein from purified WAT-MSCs. Full-length mouse IL-33 (IL-33-FL) in lysate of HEK cells expressing recombinant IL-33 and truncated mouse
IL-33 (processed, IL-33-P). Representative of two similar independent experiments. (F) Phenotyping of Il33-citrine+ stromal cells. (G) Principal component
analysis (PCA) of RNA-seq data from indicated cell populations (n = 3). (H) Gene expression data (reads per kilobase of transcript per million mapped reads;
RPKM). Representative of at least two repeat experiments. (I) Comparison of Il33+ and Il33– WAT-MSCs from adipose tissue. Genes of interest are highlighted
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CRISPR-Cas9–mediated candidate gene deletion was performed
in MSCs derived from Cas9-transgenic mice using lentiviral
vectors carrying target gene–specific guide RNAs (gRNAs; Fig. 4
A). With this approach, we determined that intercellular adhe-
sionmolecule-1 (ICAM-1) was expressed onWAT-MSCswhile its
counter-ligand LFA antigen-1 (LFA-1) was present on WAT-
ILC2s (Fig. 4 B). ICAM-1 and LFA-1 facilitate lymphocyte accu-
mulation at sites of immune activation where ICAM-1 is
up-regulated on stromal cells (Verma and Kelleher, 2017;
Walling and Kim, 2018) but can also initiate LFA-1 signaling
leading to T cell activation and proliferation (Verma and
Kelleher, 2017; Walling and Kim, 2018) and promote Th1 cell
differentiation of human T cells (Smits et al., 2002). In addition,
LFA-1 ligation has been described to mediate TCR-independent
signals, such as respiratory burst induction in neutrophils,
suggesting that LFA-1 can serve as an activating receptor in cells
by itself (Berton et al., 1992). ICAM-1 was efficiently deleted
from MSCs (Fig. 4 C). Notably, co-culture of ICAM-1 gRNA-
targeted MSCs with WT ILC2 resulted in impaired ILC2 prolif-
eration, reduced KLRG1 expression, and reduced IL-5 production
as compared with controls (Fig. 4 D). To validate this ICAM-
1–mediated interaction, we assessed the involvement of the re-
ciprocal LFA-1 ligand by CRISPR-Cas9–targeting in ILC2s.
Knockdown of LFA-1 expression on ILC2 was highly efficient,
compared with control gRNA (Fig. 4 E). Furthermore, ILC2
lacking LFA-1 expression failed to proliferate as efficiently as
control gRNA-targeted ILC2 when cultured with WT MSCs
(Fig. 4 F). Thus, an ICAM-1/LFA-1 receptor–mediated interaction
between MSCs and ILC2 enhances ILC2 proliferation.
We next examined the frequency of ILC2 in WAT from naive
LFA-1–deficient (Itgal−/−) mice and found that ILC2 numbers and
frequencies were significantly lower in the absence of LFA-
1 (Fig. 4, G and H; and Fig. S3 E). Furthermore, this deficit was
mirrored by a decrease in WAT eosinophils (Fig. 4, G and H; and
Fig. S3 E). By contrast, the proportion and number of CD4+
T cells and CD3+ cells in the WAT were not altered by the de-
letion of LFA-1 (Fig. 4, G and H; and Fig. S3 E). Thus, the absence
of LFA-1 in vivo leads to a diminution of ILC2s in adipose tissue,
and this correlated with fewer eosinophils. Our data suggest that
inefficient ILC2 proliferation may contribute to the observed
ILC2 deficit, but selective cellular adhesion may also be impor-
tant for localization and retention of ILC2 inWAT. Icam1−/− mice
have been reported to spontaneously gain weight when main-
tained on normal diet (Dong et al., 1997), and it is possible, given
our data, that the interaction of ICAM-1 with LFA-1 on ILC2s
contributes to this phenotype. Interestingly, a recent report has
(n = 3). (J) Adipose differentiation determined by lipid droplet analysis. Representative of two experiments. Scale bars, 100 µm. (K) Myocyte differentiation
determined by α-smooth muscle actin (αSMA) staining. Representative of three experiments. Scale bars, 100 µm. Data are represented as mean ± SEM. Max,
maximum.
Figure 2. ILC2s respond to MSC-derived IL-33. (A) ILC2 number at 7 d of culture with WT or IL-33–deficient (Il33−/−) MSCs. Pooled data from three ex-
periments (n = 5 or 6). (B) Frequency of Ki67+ILC2 in co-cultures at day 7. One of two similar experiments (n = 4). (C) Mean fluorescent intensity (MFI) of
intracellular IL-5 expression by ILC2s in co-cultures at day 7, determined by flow cytometry. (D) IL-5 in co-culture supernatants at day 7 determined by ELISA.
(E and F)MFI of KLRG1 (E) or of intracellular GATA3 expression by ILC2s from co-cultures at day 7 (F). Pooled data are from two experiments (n = 6 mice; C–F).
(G) IL-33 in freeze-thawed SVF supernatants analyzed by ELISA. Pooled data from three experiments (n = 7). (H) Frequency of Ki67+ ILC2s cultured for 48 h
with supernatants from I. Pooled data represent 10 separate ILC2 purifications from three independent experiments. (I and J) MFI of KLRG1 (I) or GATA3 (J)
expression by ILC2s, cultured as in H. Pooled data represent 10 separate ILC2 purifications from three independent experiments. Data are mean ± SEM. ns, not
significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; statistical analysis, one-way ANOVA with Tukey’s post hoc test (A–F), Student’s t test (G),
or paired Student’s t test (H–J).
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indicated that signaling via ICAM-1 expressed on common
lymphoid progenitors promotes their differentiation to ILC2s,
and may contribute to the proliferation of ICAM-1+ ILC2 in re-
sponse to IL-33 (Lei et al., 2018). Furthermore, stromal cells in
the mesentery supported ILC2 differentiation from ILC pre-
cursors (Koga et al., 2018). However, although we also detected
ICAM-1 on ILC2, the effect on proliferation that we observed was
dependent on ICAM-1 present on the MSCs and LFA-1 expres-
sion by ILC2s. In combination, these findings indicate the im-
portance of future studies to understand how the LFA-1 and
ICAM-1 signaling pathways, such as calcium flux and PI3K ac-
tivation, modulate ILC2 function (Berton et al., 1992; Verma and
Kelleher, 2017).
Intriguingly, our RNA sequencing (RNA-seq) data, concor-
dant with a recently published report (Dahlgren et al., 2019),
identified that WAT-MSCs highly expressed the eosinophil
chemo-attractant CCL11 (eotaxin; Fig. 1 I and Fig. S3 F), but not
CCL24 (eotaxin-2) or CCL26 (eotaxin-3; data not shown), re-
sponsible for eosinophil migration to peripheral tissues (Wen
and Rothenberg, 2016). This raised the possibility that MSCs
might contribute to eosinophil recruitment to adipose tissue and
that this may be regulated by ILC2s. For example, eotaxin is up-
regulated through IL-4 receptor (IL-4Rα) signaling (Moore et al.,
2002; Zhou et al., 2012; Lee et al., 2015; Gieseck et al., 2016),
which is a component of the IL-4 and IL-13 receptor complexes,
and is expressed by WAT-MSCs (Fig. 1 I and Fig. 5 A). Culture of
WAT-MSCs in vitro with IL-4 or IL-13 induced eotaxin expres-
sion (Fig. 5, B and C). Furthermore, ILC2 cell-culture super-
natant also drove eotaxin expression from WAT-MSCs, as
compared with control supernatant (Fig. 5 C). This effect was
dependent on WAT-ILC2–derived IL-4/IL-13 as ILC2s from
Il4−/−Il13−/− BALB/c mice failed to induce eotaxin secretion, as
compared with BALB/cWT controls (Fig. 5 D). CRISPR-mediated
IL-4Rα–gRNA targeted deletion of IL-4Rα on MSCs confirmed
the requirement for IL-4Rα–mediated signaling (Fig. 5, E and F).
We also investigated if IL-4 and IL-13 could regulate Il33-citrine
expression by WAT-MSCs. Indeed, IL-4 and IL-13 treatment
increased IL-33 expression (data not shown). Thus, ILC2-
secreted IL-4 and IL-13 can prime the expression of the
eosinophil-attracting chemokine, eotaxin, from WAT-MSCs and
may provide a potential positive feedback loop for IL-33 ex-
pression from WAT-MSCs.
To evaluate whether the interaction ofWAT-MSCs with IL-4/
IL-13–producing ILC2 mediates eosinophil recruitment in vivo,
WAT-MSCs, WT ILC2, or IL-4/IL-13–deficient ILC2s were puri-
fied, labeled with CTV, and co-cultured overnight, combined
with Matrigel, and transferred subcutaneously into naive WT
recipients (Fig. 5 G). After 48 h, theMatrigel plugs were isolated,
and flow cytometry analysis revealed that eosinophils were in-
creased when MSCs and WT ILC2 were cotransferred as com-
pared with Matrigel alone (Fig. 5 H and Fig. S3 G). Notably,
eosinophil recruitment was not observed when IL-4/IL-13–
Figure 3. WAT-MSCs induce ILC2 proliferation and type-2 cytokine production. (A) Frequency of Ki67+ILC2s and KLRG1 expression by ILC2 from ILC2
alone, or ILC2 cultured with MSCs (ILC2 + MSCs). (B) ILC2 cell counts after 7 d of co-culture. TW, transwell. Pooled data from two experiments (n = 7). (C) Flow
cytometric analysis of CTV dilution and quantification of relative CTV MFI (CTV MFI sample/CTV MFI ILC2)−1 after 7 d of co-culture. Pooled data from two
experiments (n = 7). (D) IL-5 in supernatants after 7 d of co-culture, as determined by ELISA. Pooled data from four experiments (n = 11). Data are mean ± SEM.
ns, not significant; *, P < 0.05; **, P < 0.01; ****, P < 0.0001; statistical analysis, one-way ANOVA with Freidman test (C) or Tukey’s post hoc test (B and D).
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deficient ILC2s were combined with WAT-MSCs (Fig. 5 H),
correlating with the absence of eotaxin (Fig. S3 H). IL-5 is known
to promote eosinophil retention and survival in peripheral
tissues, as well as acting as a growth and differentiation factor
for eosinophil development in the bone marrow (Wen and
Rothenberg, 2016), and maintaining eosinophils in adipose tis-
sue (Molofsky et al., 2013). However, IL-5 is unlikely to influ-
ence these Matrigel assays as both WT and IL-4/IL-13–null ILC2s
Figure 4. Ligation of LFA-1 on ILC2 by ICAM-1 onWAT-MSCs induces ILC2 proliferation and IL-5 production. (A) Schematic of CRISPR targeting knockout
co-culture assay. (B) Representative flow cytometric analysis of ICAM-1 and LFA-1 expression byWAT-MSCs and ILC2. Data representative of two independent
experiments (n = 6). (C) Representative example of MSC ICAM-1 CRISPR-Cas9–mediated knockdown. Non-targeting gRNA (Control gRNA); ICAM-1 targeting
gRNA (ICAM-1 gRNA). Pooled data from four independent experiments (n = 9 or 10). (D) Frequency of Ki67+ILC2, KLRG1 MFI on ILC2s, and IL-5 concentrations
(ELISA) from MSC ICAM-1–targeted cultures at day 10. Pooled data from 8–10 individual MSC purifications from at least two independent experiments (n =
8–10). (E) Representative example of LFA-1 CRISPR-Cas9–mediated knockdown. Non-targeting gRNA (Control gRNA); LFA-1 targeting gRNA (LFA-1 gRNA).
Pooled data from two experiments (n = 8mice). (F) Frequency of Ki67+ILC2 from ILC2 LFA-1–targeted cultures at day 10. Pooled data from eight individual MSC
purifications from two independent experiments (n = 8). (G and H) Cell numbers (G) and frequency (H) of ILC2, eosinophil, CD4+CD3+ T cell, and CD3+ T cell in
combined perigonadal and inguinal adipose tissue. Control (WT) and Itgal−/− (LFA-1-KO) mice. Data representative of two independent experiments (n = 4
mice). Data are mean ± SEM. ns, not significant; *, P < 0.05; **, P < 0.01; ****, P < 0.0001; statistical analysis, Student’s t tests (C, E, G, and H) or paired
Student’s t tests (D and F).
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Figure 5. ILC2 and MSCs coordinate eosinophil recruitment in vivo. (A) Representative flow cytometric analysis of IL-4Rα expression by WAT-MSCs.
(B) Quantitative PCR analysis of eotaxin (Ccl11) expression by purified WAT-MSCs cultured with the indicated cytokines for 48 h. Pooled data from three
experiments (n = 4). RQ, relative quantification; HRPT, hypoxanthine phosphoribosyltransferase. (C) ELISA detection of eotaxin in supernatants (at 7 d) from
WAT-MSCs and ILC2 co-cultures treated as indicated. SNT, supernatant. Pooled data from three to five independent experiments (n = 6–9). (D) Detection of
eotaxin in supernatants fromMSCs and ILC2s (WT,WT BALB/c, or Il4−/−/Il13−/− BALB/c) cultured as indicated for 7 d, as determined by ELISA. Pooled data from
two experiments (n = 4–8). (E) Representative example of IL-4Rα CRISPR-Cas9–mediated knockdown. Non-targeting gRNA (Control gRNA); IL-4Rα targeting
gRNA (IL-4Rα gRNA; n = 6). Representative of two similar experiments. (F) ELISA detection of eotaxin in supernatants from MSCs transduced with lentiviral
vectors containing non-targeting gRNA (Control gRNA) or IL-4Rα targeting gRNA (IL-4Rα gRNA), and cultured with ILC2 or recombinant IL-13 and IL-4 for 4 d
(n = 3 mice). Representative of two similar experiments. (G) Schematic of eosinophil recruitment model. (H) Flow cytometry analysis of
CD45+GR1–CD11b+SiglecF+ eosinophil recruitment to Matrigel plugs harvested fromWT recipients, shown as eosinophil percentage of CD45+ cells and absolute
number of eosinophils per Matrigel plug. Pooled data from three experiments (n = 6 experimental, and n = 15 control). Data represented as mean ± SEM. *, P <
0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; statistical analysis, repeated-measures ANOVA with Tukey’s post hoc test (C and F), one-way ANOVA (B, D,
and H), or Student’s t test (E).
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produce similar levels of IL-5 (data not shown). Together, these
data highlight the synergy between ILC2s and WAT-MSCs and
indicate the potential for ILC2-derived IL-4/IL-13–dependent
induction of eotaxin production from MSCs to enhance eosino-
phil recruitment. IL-4/IL-13–deficient mice have been reported
to have normal numbers of WAT eosinophils (Molofsky et al.,
2013), though these mice do show eosinophil deficits in other
tissues, especially upon immune challenge (Fallon et al., 2002).
Furthermore, others have indicated that such a network may
play a role in recruiting eosinophils to the liver during fibrosis
(Gieseck et al., 2016). Further studies will be required to deter-
mine the potential role of this pathway in vivo during homeo-
stasis and during dysregulation, and to understand the interplay
between ICAM-1–LFA-1 signals and ILC2-derived IL-4/IL-13.
In summary, we show that adipose MSCs can help sustain the
type-2 microenvironment by supporting the proliferation, acti-
vation, and type-2 cytokine production of ILC2, and by re-
sponding to ILC2-derived IL-4 and IL-13, up-regulate eotaxin to
promote eosinophil recruitment. Thus, MSCs can provide a ni-
che for the maintenance of type-2 immune homeostasis in adi-
pose tissue.
Materials and methods
Mice
Il4−/−Il13−/− (McKenzie et al., 1999) mice were backcrossed on a
BALB/c background for six generations, and control BALB/c
mice were bred in-house. Il7raCre (Schlenner et al., 2010),
Rorafl/fl (Oliphant et al., 2014), Il33cit/cit (Hardman et al., 2013),
Tie2-GFP mice (Tg[TIE2GFP]287Sato/J; Jackson Laboratory),
Rosa26-Cas9 knockin (Gt[ROSA]26Sortm1.1(CAG-cas9*,-EGFP)Fezh;
Jackson Laboratory), and Itgal−/− (Itgaltm1Bll; Jackson Laboratory)
were on a C57Bl/6 background. C57Bl/6 Jax controls were bred
in-house. All mice were maintained in the Medical Research
Council ARES animal facility under specific pathogen–free
conditions. All animal experiments undertaken in this study
were done with the approval of the UK Home Office.
Isolation of naive WAT-MSCs and naiveWAT-ILC2 from C57BL/
6 mice
WAT was mechanically dissociated in RPMI-1640, and digested
with collagenase I (Life Technologies) and DNase I (Roche) at
37°C while shaking. Lin–CD45–EpCAM–CD31–CD24–PDGFRα+
CD34+Sca1+podoplanin+ WAT-MSCs and lineage–ST2+EpCAM–
WAT-ILC2s were sorted by flow cytometry using Sony iCyt
Synergy (Sony) to >95% purity. ILC2s were also isolated from
mesenteric lymph node (MLN) as lineage–ST2+ cells. With the
exception of the Matrigel study, all ILC2 and MSC assays were
performed with cells isolated from naive C57BL/6 mice.
Flow cytometry
Single cells were incubated with anti-mouse CD16/32 (BioXCell)
to block Fc receptors and stained as indicated: PGDFRα PE
(APA5; BioLegend), CD34 Alexa Fluor 660 (RAM34; eBioscience),
podoplanin PECy7 (8.1.1; BioLegend), EpCAM (G8.8; BioLegend),
Sca1 APC-Cy7 (D7; BioLegend), CD24 (M1/69; BioLegend),
CD31 (390; BioLegend), CD29 Alexa Fluor 700 (HMBeta1-1;
BioLegend), ST2 PerCP efluor710 (RM-ST2; eBioscience), CD4
BV785 (RM4-5; BioLegend), CD45 (bv510 30-F11; BioLegend),
CD4 BV785 (RM4-5; BioLegend), ef780 live dead (eBioscience),
SiglecF af647 (E50-2440; BD Biosciences), CD11b (M1/70; Bio-
Legend), CD11c PE (N418; BioLegend), Ly6G PerCP efluor710
(1A8-Ly6g; eBioscience), IL-5 APC (TRFK5; BioLegend), IL-13 PE
(eBio13A; R&D Systems), GATA3 BV711 (L50-823; BD Horizon),
RORγt PE (AFKJS-9; eBioscience), FOXP3-PECy7 (FJK-16S;
eBioscience), Lineage B220 (RA3-6B2), CD3 (17A2), CD4 (GK1.5),
CD8s (53–6.7), CD11b (M1/70), CD11c (N418), CD19 (eBio1D3),
FCεR1 (MAR-1), DX5 (DX5), F480 (BM8), GR1 (RB6-8C5), NK1.1
(PK136), TCRβ (H57-597), and Ter119 (TER-119; efluor450;
eBioscience).
For intracellular and nuclear staining, cells were processed
using the Foxp3/Transcription Factor Kit (eBioscience). For in-
tracellular IL-5 and IL-13 detection, cells were cultured with
PMA (50 ng/ml), ionomycin (500 ng/ml), and 1× protein
transport inhibitor (eBioscience) in culture media, RPMI-1640,
10% FCS plus penicillin/streptomycin and 2-mercaptoethanol,
for 4 h. Flow cytometry analysis was performed on a BD Fortessa
instrument. Cell numbers were quantified based on precision
count beads (BioLegend), and flow cytometry data were ana-
lyzed using FlowJo (version 9.9). Dead cells were excluded from
analysis.
RNA-seq
Cells were flow sorted into in RPMI-1640, 10% FCS plus pen-
icillin/streptomycin, 2-mercaptoethanol and transferred to
Trizol (Life Technologies). RNA was extracted using RNeasy
kits and reagents (Qiagen). DNA was digested using Turbo
DNase (Ambion). RNA was concentrated using an RNeasy
Micro Kit (Qiagen) and assessed using a Bioanalyser (Agilent).
RNA was processed for RNA-sequencing using an Ovation
RNA-seq System V2 (Nugen), fragmented using the Covaris
M220, and bar-coded using Ovation Ultralow Library Sys-
tems (Nugen). Samples were sequenced using an Illumina
Hiseq4000 (Cancer Research UK Cambridge Institute), and
sequence data were aligned using Tophat2 with Partek Flow.
RNA-seq analysis was performed using Partek Genomics Suite
software, version 6.16.
In vitro cell culture and differentiation assays
For co-culture assays, 10,000 WAT-ILC2s were cultured with
100,000 WAT-MSCs (or at a ratio of 1:10 if fewer cells were
available), in RPMI-1640, 10% FCS plus penicillin/streptomycin,
2-mercaptoethanol, and where applicable, polycarbonate trans-
wells were used (0.4 µm; Scientific Laboratory Supplies). To
maintain ILC2 survival, rmIL-7 (10 ng/ml; BioLegend) was in-
cluded in all assays with ILC2s as well as controls, including
when co-cultured with MSCs. The following cytokines were
added to cultures as indicated: rmIL-13 (20 ng/ml; BioLegend),
rmIL-4 (20 ng/ml; BioLegend), and rmIL-33 (10 ng/ml; Bio-
Legend). IL-5 and eotaxin were detected by ELISAs (eBioscience
and Peprotech, respectively), or eotaxin was analyzed using the
MAGPIX assay (Luminex).
For adipocyte differentiation assays, total SVF from peri-
gonadal fat was dispersed by digestion with collagenase type II
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before WAT–IL-33–citrine+MSCs were isolated by flow sorting.
Cells were grown to confluence in growth media, high-glucose
DMEM (glucose 25 mM; Sigma-Aldrich) and 1% penicillin/
streptomycin (Sigma-Aldrich) with 10% neonatal calf serum. For
adipose cell differentiation, cells were cultured for a further 10 d
in growth media with 10% FBS supplemented with 3-isobutyl-
1-methylxanthine (0.5 mM), dexamethasone (Sigma-Aldrich),
and insulin (Sigma-Aldrich). LipidTOX Red staining (Thermo
Fisher Scientific) was used to identify lipid droplets, and cul-
tures were imaged using an EVOS Cell image system (Thermo
Fisher Scientific).
For smooth muscle differentiation assays, cells were plated at
2,600 cells/cm2 and cultured with platelet-derived growth factor
(PDGF)–BB (10 ng/ml; Peprotech) and TGFβ1 (2 ng/ml; Pepro-
tech) in DMEM supplemented with 10% FCS, glutamine, peni-
cillin, and streptomycin for 7 d. Growth factors were replenished
every 2 d. Cells from aortic adventitia were treated in parallel as
a positive control. To measure proliferation, EdU was added to
the media 4 h before fixation in 4% formaldehyde. EdU detection
was performed using the Click-it Plus 647 kit (c10640; Life
Technologies) following the manufacturer’s instructions and
differentiation assessed by staining with Alexa Fluor 594–
conjugated anti–α-smooth muscle actin antibody (ab202368;
Abcam) or control IgG (ab202368; Abcam).
Ligand screen using CRISPR-Cas9 targeting
Lentiviral vectors were generated by transfecting HEK293(t)
cells with TransIT-LT1 transfection reagent (Cambridge Biosci-
ence) along with the plasmids psPAX2, pMD2.G, and lentiGuide-
Puro (Addgene) that had been modified to express BFP and
individual targeting gRNA (or random controls), designed ac-
cording to the Broad GPP genome-wide Brie Library (Addgene).
Lentivirus-containing supernatants were harvested and lenti-
viral particles concentrated using Lenti-X (Clontech). MSCs
derived from the Cas9-expressing Rosa26-Cas9 knockin mice
were plated on a flat-bottom 96-well plate (104/well), and after
24 h transduced with respective lentiviral constructs. At day 6 of
culture, purified ILC2s (5 × 103) were added to the wells and
cultured for a further 4 d (with IL-7 as described in In vitro cell
culture and differentiation assays). At day 10 of culture, MSCs
and ILC2 were analyzed by flow cytometry, and cell super-
natants harvested for IL-5 ELISA.
Purified ILC2 from Cas9-expressing Rosa26-Cas9 knockin
mice were plated on a round-bottom 96-well plate at 5 × 103
ILC2 per well, and cultured for 2 d in complete RPMI (RPMI-
1640, 10% FCS plus penicillin/streptomycin, 2-mercaptoetha-
nol), and rmIL-7 and rmIL-33 (both interleukins at 10 ng/ml;
BioLegend) before being transduced with respective lentiviral
constructs. 4 d after transduction, Lin–CD45+BFP-positive ILC2s
were purified using flow cytometry and plated on round-
bottom 96-well plates, 5 × 103 ILC2 per well. Target gene
knockout was confirmed at this point with an aliquot of ret-
rovirally transduced BFP-positive ILC2. Transduced ILC2s were
then cultured for 3 d in complete RPMI with rmIL-7, but
without rmIL-33 before co-culturing with MSCs for a further 4
d. MSCs (separately purified biological replicates) were flow-
cytometrically sorted and plated in a flat-bottom 96-well plate
4 d before co-culturing with either target gene knockout or
control transduced ILC2s. ILC2s were then harvested and an-
alyzed by flow cytometry.
Western analysis of IL-33
Tissues were homogenized in PBS with protease inhibitor 1×
cOmplete, EDTA-free (Sigma-Aldrich), and analyzed by SDS-
PAGE on NuPAGE Novex 12% Bis-Tris mini gels (Invitrogen)
with 3-(N-morpholino)propanesulfonic acid (MOPS) running
buffer (Invitrogen) according to the manufacturer’s in-
structions. All samples were reduced by heating to 95°C for
3 min in SDS-PAGE buffer containing 2% 2-mercaptoethanol.
Proteins were transferred to nitrocellulose membranes (In-
vitrogen) and detected by Western blotting for mouse IL-33
using goat anti–IL-33 polyclonal antibody (AF3626; R&D Sys-
tems) at 1:1,000 dilution, as described previously (Scott et al.,
2018). Immunoreactive proteins were identified with HRP-
conjugated anti-goat (HAF109; R&D Systems) and Supersignal
West Femto substrate (34095; Pierce).
Cell imaging
Mice were perfused using 40 ml PBS vehicle control or 40 ml
PBS containing 200 mg Lycopersicon esculentum (Tomato) lectin
(Vector), followed by 40 ml PBS. Tissues were fixed in
phosphate-buffered 1% methanol-free formaldehyde (Thermo
Fisher Scientific), transferred to 30% sucrose, embedded in 15%
sucrose + 7.5% porcine skin gelatin (Sigma-Aldrich) in PBS, and
flash-frozen in isopentane at −80°C. 10-µM sections were
mounted on Superfrost Plus slides (Thermo Fisher Scientific)
and blocked using 1% donkey serum (Jackson Immunor-
esearch) in 0.05% Triton X-100 in PBS, and citrine was de-
tected using polyclonal rabbit anti-GFP antibody (5 µg/ml; Life
Technologies) followed by Alexa Fluor 488–labeled polyclonal
donkey anti-rabbit antibody (4 µg/ml). Nuclei were stained
using DAPI (300 nM) and coverslips mounted using Prolong
Gold (Invitrogen). Sections were imaged using Zeiss 710.
Anti–smooth muscle actin (ab202368; Alexa Fluor 594; Abcam)
or IgG2a (ab178001; Alexa Fluor 594; Abcam) and EdU Click-iT
kit (Thermo Fisher Scientific) were used to analyze smooth
muscle differentiation assays and imaged using a Nikon HCA
system.
For fat-associated lymphoid cluster analysis, tissues were
fixed in 2% paraformaldehyde (Sigma-Aldrich), washed in PBS,
and permeabilized with 1× Triton X-100 (Sigma-Aldrich) while
shaking (Luckham Rotatest R100). Samples were washed,
blocked using 10% horse serum, and incubated with primary
antibodies at 4°C overnight on a gyratory rocker (Stuart).
Samples were washed and incubated with a secondary antibody
cocktail for 1 h on ice and stained with DAPI. Antibodies used for
staining were anti-CD45 FITC (30-F11; eBioscience), then rabbit
anti-FITC-488 (A-11090; Thermo Fisher Scientific); goat anti-IL-
33 (AF3626; R&D Systems), then donkey anti-goat-555 (A-21432;
Thermo Fisher Scientific); and rat anti-CD3-ef660 (17A2; eBio-
science). Tissues were washed and mounted on slides with
VectorShield mounting medium (Vector Labs). Confocal images
of slides were obtained using the Zeiss LSM 780 confocal
microscope.
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Matrigel adoptive transfers
WAT-MSCs were purified from naive BALB/c mice. ILC2s were
purified from WT BALB/c or Il4−/−Il13−/− BALB/c mice injected
intraperitoneally with IL-25 and IL-2/anti–IL-2 complex (rmIL-2;
0.5 µg/mouse; BioLegend) and anti–IL-2 JES6-1A12 (0.25 µg/
mouse; 2BScientific) preincubated at 37°C to form a complex and
rmIL-25 (1 µg/mouse; Janssen) on 3 consecutive d. Isolated
WAT-MSCs and ILC2s were co-cultured (MSCs + WT ILC2 or
MSCs + IL-13/IL-4–deficient ILC2) at a ratio of 1:1 (100,000 of
each) overnight in complete RPMI with IL-7 (10 ng/ml). The
combined cells were then resuspended at 2 × 105 per 100 µl of
Matrigel (Phenol Red-Free Corning), and injected subcutane-
ously into either the left or right inguinal fat pad of the same
mouse. Matrigel plugs were dissected 48 h later, mechanically
dissociated in RPMI-1640, digested with collagenase I (Life
Technologies) and DNase I (Roche) at 37°C while shaking, and
passed through a filter to obtain a single-cell suspension for
analysis by flow cytometry.
Statistical analysis
Graphpad Prism software was used for all statistical analysis.
RNA-seq analysis was performed using Partek Genomics Suite
software, version 6.16.
Data availability
The accession nos. for RNA sequencing datasets reported in this
paper have been deposited with the Gene Expression Omnibus
under accession no. GSE132738.
Online supplemental material
Fig. S1 shows the ILC2 andMSC populations in theWATs. Fig. S2
shows gating strategies. Fig. S3 shows gating strategies and ad-
ditional control experiments.
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